Journal of Medical Sciences (Jan 2021)

Lycopene abrogates ifosfamide-induced fanconi syndrome in albino rats

  • Elias Adikwu,
  • Bonsome Bokolo,
  • Dorcas Okayo Okoroafor

DOI
https://doi.org/10.4103/jmedsci.jmedsci_84_19
Journal volume & issue
Vol. 41, no. 3
pp. 116 – 122

Abstract

Read online

Background: Treatment modalities for Fanconi syndrome caused by ifosfamide (IFO) are very limited. This study assessed the protective effect of lycopene (LYP) against IFO-induced Fanconi syndrome in albino rats. Methods: Forty adult male albino rats randomized into eight groups of n = 5 were used. Group A (Control) was treated intraperitoneally (IP) with normal saline (0.2 mL), whereas groups B–D were treated orally with LYP (10, 20, and 40 mg/kg) daily for 5 days, respectively. Group E was treated IP with IFO (80 mg/kg) daily for 5 days, whereas groups F–H were pretreated orally with LYP (10, 20, and 40 mg/kg) before IP treatment with IFO (80 mg/kg) daily for 5 days. After treatment, the rats were anesthetized; blood samples were collected and evaluated for serum biochemical biomarkers. Kidneys were excised, weighed and evaluated for oxidative stress markers and histology. Results: Significant (P < 0.001) increases in serum creatinine, urea, and uric acid levels with significant (P < 0.001) decreases in glucose, phosphate, magnesium, calcium, potassium, sodium, chloride, and bicarbonate levels were observed in IFO-treated rats when compared to control. Significant (P < 0.001) decreases occurred in kidney superoxide dismutase, catalase, glutathione (GSH), and GSH peroxidase levels with significant (P < 0.001) increases in malondialdehyde levels in IFO-treated rats in comparison to control. Glomerulus with sclerosis, lipid accumulation, and tubular necrosis were observed in the kidneys of IFO-treated rats. The aforementioned changes were significantly abrogated in rats pretreated with LYP 10 mg/kg (P < 0.05), 20 mg/kg (P < 0.01), and 40 mg/kg (P < 0.001) when compared to IFO-treated rats. Conclusions: LYP may be useful as treatment for Fanconi syndrome caused by IFO.

Keywords